Company profile

The company was established in April 2008 in Lengshuitan District of Yongzhou City, Hunan Province, with a registered capital of 10 million yuan. As a "specialized, sophisticated, distinctive, and innovative" small giant enterprise in Hunan Province, a national high-tech enterprise, and a provincial-level enterprise technology center, the company's mission is "safeguarding global health" and is committed to enhancing the production capacity and quality of Artemisinin through technological innovation, contributing to the global anti-malaria cause.

In 2023, the company's production and sales volume of Artemisinin reached nearly 100 tons, consistently ranking among the top three in the domestic market. Leveraging over a decade of deep cultivation and accumulation, the company has core competitiveness in the entire industry chain of Artemisia Annua cultivation, extraction, and deep processing, especially in the breeding of new varieties of Artemisia Annua and the extraction of high-purity Artemisinin, which is in a leading position in the industry.

The company has established stable Artemisia Annua planting bases, maintaining an annual planting area of over 6,700 hectares in Yongzhou City, which accounts for about half of the national total. It possesses multiple patents in areas such as Artemisinin extraction and new variety breeding. By employing advanced technologies like molecular marker-assisted selection and genomic selection, it has successfully developed new high-yield and high-content Artemisia Annua varieties, aiming to increase Artemisinin content to over 2%.

The company continuously has developed a series of products including Artemisia Annua oil, Artemisia Annua wax, and Artemisia Annua powder, which are widely used in pharmaceuticals, health products, and cosmetics. This enhances the added value of Artemisia Annua and broadens its market applications. The quality is stable and reliable, with exports to countries such as India and those in Europe and America, earning a good reputation in international markets.

In the next five years, the company will continue to deepen its core business in Artemisia Annua while actively expanding into the health industry and international markets. On one hand, it will increase investment in research and development to advance new variety breeding and tackle key technological challenges to enhance core competitiveness. On the other hand, it will develop more high-value-added Artemisia Annua derivative products through deep processing to expand market space and actively participate in international cooperation to consolidate existing international markets while exploring emerging markets to enhance brand influence.